Research Analysts Offer Predictions for YMAB FY2025 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Y-mAbs Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will earn ($0.67) per share for the year. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.64) per share.

Several other equities research analysts also recently issued reports on the company. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Friday, January 10th. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Y-mAbs Therapeutics currently has a consensus rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Trading Up 0.5 %

NASDAQ:YMAB opened at $6.19 on Wednesday. Y-mAbs Therapeutics has a one year low of $6.01 and a one year high of $20.90. The business’s 50-day simple moving average is $9.10 and its 200 day simple moving average is $11.86.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the firm earned ($0.18) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Y-mAbs Therapeutics during the third quarter valued at $44,000. China Universal Asset Management Co. Ltd. lifted its position in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the last quarter. Intech Investment Management LLC acquired a new position in Y-mAbs Therapeutics during the 3rd quarter valued at about $133,000. SG Americas Securities LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $210,000. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.